Scholarlink

<p>Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common monogenic genetic disorders, caused by mutations in receptor PKD1 or ion channel PKD2, and is characterized by progressive renal cyst development with additional hepatic and extrarenal manifestations. As effective treatments for ADPKD remain limited, further investigation into the function and regulation of PKD proteins is needed. Using biotin-based proximity labeling combined with mass spectrometry in human embryonic kidney (HEK) cells, here we identify Ras association domain family member 4 (RASSF4) as a potential PKD2-interacting protein. The association between PKD2 and RASSF4 is validated by co-immunoprecipitation, bimolecular fluorescence complementation, and in vitro binding assays in HEK cells and mouse kidneys. Functional analyses using two-electrode voltage clamp electrophysiology in <i>Xenopus</i> oocytes demonstrate that RASSF4 enhances PKD2 channel activity without affecting its membrane expression. In vivo studies in larval zebrafish show that RASSF4 over-expression alleviates, whereas Rassf4 knockdown exacerbates, Pkd2 knockdown–associated phenotypes, including tail curling, pronephric cyst formation, renal filtration defects, and motor dysfunction. Disruption of the RASSF4/PKD2 interaction using a blocking peptide (amino acid P134–S168) abolishes RASSF4-mediated stimulation of PKD2 channel function and phenotypic rescue, while worsening disease severity, likely by interfering with endogenous complex formation. Mechanistically, RASSF4 enhances the functionally critical intramolecular interaction between the PKD2 N- and C-termini and suppresses RAS/MAPK signaling in HEK cells. Together, these findings identify RASSF4 as a PKD2 regulator and suggest that the RASSF4/PKD2 complex represents a potential therapeutic target for ADPKD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Regulation of the PKD2 channel function and associated disease phenotypes by RASSF4

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月15日

查看全文
  • Rui Tian,
  • Wanyi Fang,
  • Wenbin Yuan,
  • Shi Li,
  • Yixin Wu,
  • Xueying Dong,
  • Wei Liu,
  • Jinghua Kong,
  • Xiaoling Deng,
  • Rui Zhang,
  • Hao Lyu,
  • Shuai Xiao,
  • Dong Guo,
  • Qi Zhang,
  • Declan William Ali,
  • Marek Michalak,
  • Cefan Zhou,
  • Jingfeng Tang,
  • Xing-Zhen Chen

摘要

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common monogenic genetic disorders, caused by mutations in receptor PKD1 or ion channel PKD2, and is characterized by progressive renal cyst development with additional hepatic and extrarenal manifestations. As effective treatments for ADPKD remain limited, further investigation into the function and regulation of PKD proteins is needed. Using biotin-based proximity labeling combined with mass spectrometry in human embryonic kidney (HEK) cells, here we identify Ras association domain family member 4 (RASSF4) as a potential PKD2-interacting protein. The association between PKD2 and RASSF4 is validated by co-immunoprecipitation, bimolecular fluorescence complementation, and in vitro binding assays in HEK cells and mouse kidneys. Functional analyses using two-electrode voltage clamp electrophysiology in Xenopus oocytes demonstrate that RASSF4 enhances PKD2 channel activity without affecting its membrane expression. In vivo studies in larval zebrafish show that RASSF4 over-expression alleviates, whereas Rassf4 knockdown exacerbates, Pkd2 knockdown–associated phenotypes, including tail curling, pronephric cyst formation, renal filtration defects, and motor dysfunction. Disruption of the RASSF4/PKD2 interaction using a blocking peptide (amino acid P134–S168) abolishes RASSF4-mediated stimulation of PKD2 channel function and phenotypic rescue, while worsening disease severity, likely by interfering with endogenous complex formation. Mechanistically, RASSF4 enhances the functionally critical intramolecular interaction between the PKD2 N- and C-termini and suppresses RAS/MAPK signaling in HEK cells. Together, these findings identify RASSF4 as a PKD2 regulator and suggest that the RASSF4/PKD2 complex represents a potential therapeutic target for ADPKD.